Alpha-lipoic acid modulates ovarian surface epithelial cell growth

Gynecologic Oncology

Volumn 103, Issue 1, 2006, Pages 45-52

  Vig Varga, E ^a   Benson, Eric A ^a   Limbil, Tony L ^a   Allison, Bernadette M ^a   Goebl, Mark G ^a   Harrington, Maureen A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha lipoic acid (ALA); Apoptosis; Inflammation; Nuclear factor B (NF B); Ovarian cancer; Ovarian surface epithelial cells; p27kip1; Tumor necrosis factor alpha (TNF )

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ASCITES FLUID; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; OVARIAN NEOPLASMS; OVARY; THIOCTIC ACID; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748529374     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.01.060     Document Type: Article

References (42)

1. Roby K.F., Taylor C.C., Sweetwood J.P., Cheng Y., Pace J.L., Tawfik O., Persons D.L., Smith P.G., and Terranova P.F. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogen 21 4 (2000) 585
2. Barnholtz-Sloan J.S., Schwartz A.G., Qureshi F., Jacques S., Malone J., and Munkarah A.R. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am. J. Obstet. Gynecol. 189 4 (2003) 1120-1127
3. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
4. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 (2004) 405-406
5. Ness R.B., and Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. 1 (1999) 1459-1467
6. McCann S.E., Moysich K.B., and Mettlin C. Intakes of selected nutrients and food groups and risk of ovarian cancer. Nutr. Cancer 39 (2001) 19-28
7. Fleischauer A.T., Olson S.H., Mignone L., Simonsen N., Caputo A., and Harlap S. Dietary antioxidants, supplements and risk of epithelian ovarian cancer. Nutr. Cancer 40 (2001) 80-92
8. Drisko J.A., Chapman J., and Hunter V.J. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J. Am. Coll. Nutr. 22 (2003) 118-123
9. Rodrigues-Burford C., Barnes D.K., Oeschlager D.K., Myers R.B., Talley L.I., Partridge E.E., et al. Clin. Cancer Res. 8 (2002) 202
10. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Kato I., Koenig K.L., and Shore R.E. Aspirin and epithelial ovarian cancer. Prev. Med. 33 6 (2001) 682-768
11. Yoo C.G., Lee S., Lee C.T., Kim Y.W., Han S.K., and Shim Y.S. Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells. Am. J. Physiol.: Lung Cell. Mol. Physiol. 280 (2001) L3-L9
12. Stark L.A., Din F.V., Zwacka R.M., and Dunlop M.G. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 15 (2001) 1273-1275
13. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
14. Fries J.F., and Bruce B. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. J. Rheumatol. 30 (2003) 2226-2233
15. Chan F.K., Chung S.C., Suen B.Y., Lee Y.T., Leung W.K., Leung V.K., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. Clinical trial, randomized controlled trial. N. Engl. J. Med. 344 (2001) 967-973
16. Somchit N., Sanat F., Gan E.H., Shahrin I.A., and Zuraini A. Liver injury induced by the non-steroidal anti-inflammatory drug mefenamic acid. Singapore Med. J. 45 (2004) 530-532
17. Packer L., Kraemer K., and Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17 (2001) 888-895
18. Kramer K., Hoppe P., and Packer L. R-alpha-lipoic acid in health and disease prevention. Nutraceuticals (2001), Marcel Dekker, Inc., New York 129-164
19. Suzuki Y.J., Aggarwal B.B., and Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells. Biochem. Biophys. Res. Commun. 189 3 (1992) 1709-1715
20. Packer L., Tritschler H.J., and Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radical Biol. Med. 22 1-2 (1997) 359-378
21. Stoll S., Hartmann H., Cohen S.A., and Muller W.E. The potent free radical scavenger alpha-lipoic acid improves memory in aged mice: putative relationship to NMDA receptor deficits. Pharmacol. Biochem. Behav. 46 (1993) 799-805
22. Packer L., Witt E.H., and Tritschler H.J. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biol. Med. 19 (1995) 227-250
23. Freisleben H.J., Neeb A., Lehr F., and Ackermann H. Influence of selegiline and lipoic acid on the life expectancy of immunosuppressed mice. Arzneim.-Forsch. 47 (1997) 776-780
24. Zhang W.J., and Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 15 (2000) 2423-2432
25. Mantovani G., Maccio A., Melis G., Mura L., Massa E., and Mudu M.C. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidant alpha-lipoic acid and N-acetyl cysteine. Int. J. Cancer 86 (2000) 842-847
26. Ahluwalia A., Hurteau J.A., Bigsby R.M., and Nephew K.P. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol. Oncol. 82 (2001) 299-304
27. Van De Mark K., Chen J.S., Steliou K., Perrine S.P., and Faller D.V. Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J. Cell. Physiol. 194 (2003) 325-340
28. Duvoix A., Blasius L., Delhalle S., Schnekenburger M., Morceau F., Henry E., et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 223 (2005) 181-190
29. Polyak K., Lee M.-H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 (1994) 59-66
30. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
31. Bast A., and Haenen G.R. Lipoic acid: a multifunctional nutraceutical. In: Kramer K., Hoppe P., and Packer L. (Eds). Nutraceuticals in Health and Disease Prevention (2001), Marcel Dekker, Inc., New York 113-128
32. Smith A.R., Shenvi S.V., Widlansky M., Suh J.H., and Hagen T.M. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem. 11 9 (2004) 1135-1146
33. Teichert J., Hermann R., Ruus P., and Preiss R. Plasma kinetics, metabolism and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J. Clin. Pharmacol. 43 (2003) 1257-1267
34. Bustamante J, Lodge KJ, Marcocci I, Tritschler J, Packer L, Rihn H. α-Lipoic acid in liver metabolism and disease. Free Radical Biol. Med. 24 (6) 1023-39.
35. Hwang C.Y., Ryu Y.S., Chung M.S., Kwang D.K., Park S.S., Chae S.K., et al. Thiredoxin modulates activator protein 1 (AP-1) activity and p27kip1 degradation through direct interaction with Jab1. Oncogene 23 (2004) 8868-8875
36. Chiarle R., Budel L.M., Skolnik J., Frizzera G., Chilosi M., Corato A., et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95 (2000) 619-626
37. Kisseleva E., Becker M., Lemm M., and Fichtner I. Early macrophage and cytokine response during the growth of immunogenic and non-immunogenic murine tumors. Anticancer Res. 21 5 (2001) 3477-3484
38. Moysich K.B., Mettlin C., Piver M.S., Natarajan N., Menezes R.J., and Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol., Biomarkers Prev. 10 8 (2001) 903-906
39. Mills G.B. Mechanisms underlying chemoprevention of ovarian cancer. Clin. Cancer Res. 8 1 (2002) 7-10
40. Tak P.P., and Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107 (2001) 7-11
41. Marino M.W., Dunn A., Grail D., Inglese M., Noguchi Y., Richards E., et al. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. 94 (1997) 8093-8098
42. Wu S., Boyer C.M., Whitaker R.S., Berchuck A., Wiener J.R., Weinberg J.B., et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Can. Res. 53 8 (1993) 1939-1944